网站文字资料614.docVIP

About Us Kunming Biomed International (KBI), located in southwest China, is a contract research organization (CRO) providing preclinical research services, specialized on non-human primates. The core competency of KBI stems from our expertise in developing and running specialized primate animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. A big animal colony combined with experienced research and scientific study teams can offer “one-stop service” which ensures the detailed quality from animal to study. We also conduct adjacency studies in PK/PD, in vivo pharmacology and preliminary toxicology. Our experienced research and management team offers cost effective study of the highest quality while applying the highest standards of animal welfare and animal ethics. KBI incorporates all standards necessary to achieve AAALAC accreditation and GLP compliance. KBI has a partner research institute - the National Engineering Research Center?of Biomedicine and Animal Science (NERCBA), and close collaborations with Morningside portfolio companies and other leading pharmacology CROs in China. About Us\ Executive Management Team Dr. Weizhi JI, CEO 40 years’ experience in non-human primate research Former Director of Kunming Inst. of Zoology, CAS; Director of Kunming Primate Research Center, CAS; Visiting Professor at the University of Wisconsin; Research Scientist at Oregon National Primate Research Center and Smithsonian Institution. Current Committee Members of IUCN/SSC Primate Specialist Group and IUCN/SSC Captive Breeding Specialist Group; Principal of Chinese Association For Laboratory Animal Sciences NHP Expert Panel; Council Member of China Zoological Society Reproductive Biology Expert Panel. Chaired a number of State Key Projects, with over 90 publications in well-known international biology journals. Dr. Wayne LI, General Manager Doctoral Degree of Analytical Chemistry